Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study

Charlotte Skriver*, Christian Dehlendorff, Michael Borre, Klaus Brasso, Signe Benzon Larsen, Anne Tjønneland, Anton Pottegård, Jesper Hallas, Henrik Toft Sørensen, Søren Friis

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Purpose: Epidemiologic studies suggest that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. We examined these associations overall and according to clinical and lifestyle parameters. Methods: We identified male participants in the Danish Diet, Cancer and Health Study (n = 26,339), holding information on anthropometric measures and lifestyle factors. From Danish nationwide registries and medical records, we retrieved complete prescription histories and prostate cancer occurrence and characteristics. Cox regression was used to estimate hazard ratios (HRs) for prostate cancer associated with low-dose aspirin or nonaspirin NSAID use, overall and by clinical characteristics, anthropometric measures, and lifestyle factors. Results: We identified 1,927 prostate cancer cases during a median follow-up of 17.0 years. Low-dose aspirin use was not associated with overall prostate cancer risk, but a reduced HR for nonaggressive prostate cancer (high use [≥ 1,825 tablets]: 0.79; 95% confidence interval (CI) 0.60–1.04) and an increased HR for aggressive disease (high use: 1.27; 95% CI 1.00–1.61) was observed with low-dose aspirin use. Long-term, high-intensity use (≥ 10 years with ≥ 0.25 defined daily doses/day) of nonaspirin NSAIDs was associated with an increased HR for prostate cancer (1.35, 95% CI 0.99–1.84), confined to localized and nonaggressive disease. No consistent variation in HRs was seen in analyses stratified by height, body mass index, smoking, and alcohol use. Conclusion: Low-dose aspirin or other NSAID use was not associated with reduced prostate cancer risk, neither overall nor according to anthropometric measures, smoking, or alcohol use. The variation according to outcome characteristics warrants further investigation.

OriginalsprogEngelsk
TidsskriftCancer Causes and Control
Vol/bind31
Udgave nummer2
Sider (fra-til)139-151
ISSN0957-5243
DOI
StatusUdgivet - feb. 2020

Fingeraftryk

Prostatic Neoplasms
Diet
Health
Pharmaceutical Preparations
Neoplasms
Confidence Intervals
Smoking
Alcohols
Medical Records
Prescriptions
Registries
Epidemiologic Studies
Body Mass Index

Citer dette

Skriver, C., Dehlendorff, C., Borre, M., Brasso, K., Larsen, S. B., Tjønneland, A., ... Friis, S. (2020). Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. Cancer Causes and Control, 31(2), 139-151. https://doi.org/10.1007/s10552-019-01252-5
Skriver, Charlotte ; Dehlendorff, Christian ; Borre, Michael ; Brasso, Klaus ; Larsen, Signe Benzon ; Tjønneland, Anne ; Pottegård, Anton ; Hallas, Jesper ; Sørensen, Henrik Toft ; Friis, Søren. / Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. I: Cancer Causes and Control. 2020 ; Bind 31, Nr. 2. s. 139-151.
@article{5ea27eceac9b438d90dca2e35c93207a,
title = "Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study",
abstract = "Purpose: Epidemiologic studies suggest that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. We examined these associations overall and according to clinical and lifestyle parameters. Methods: We identified male participants in the Danish Diet, Cancer and Health Study (n = 26,339), holding information on anthropometric measures and lifestyle factors. From Danish nationwide registries and medical records, we retrieved complete prescription histories and prostate cancer occurrence and characteristics. Cox regression was used to estimate hazard ratios (HRs) for prostate cancer associated with low-dose aspirin or nonaspirin NSAID use, overall and by clinical characteristics, anthropometric measures, and lifestyle factors. Results: We identified 1,927 prostate cancer cases during a median follow-up of 17.0 years. Low-dose aspirin use was not associated with overall prostate cancer risk, but a reduced HR for nonaggressive prostate cancer (high use [≥ 1,825 tablets]: 0.79; 95{\%} confidence interval (CI) 0.60–1.04) and an increased HR for aggressive disease (high use: 1.27; 95{\%} CI 1.00–1.61) was observed with low-dose aspirin use. Long-term, high-intensity use (≥ 10 years with ≥ 0.25 defined daily doses/day) of nonaspirin NSAIDs was associated with an increased HR for prostate cancer (1.35, 95{\%} CI 0.99–1.84), confined to localized and nonaggressive disease. No consistent variation in HRs was seen in analyses stratified by height, body mass index, smoking, and alcohol use. Conclusion: Low-dose aspirin or other NSAID use was not associated with reduced prostate cancer risk, neither overall nor according to anthropometric measures, smoking, or alcohol use. The variation according to outcome characteristics warrants further investigation.",
keywords = "Aspirin, Cohort study, Epidemiology, Nonsteroidal anti-inflammatory drugs, Prostate neoplasms, Risk",
author = "Charlotte Skriver and Christian Dehlendorff and Michael Borre and Klaus Brasso and Larsen, {Signe Benzon} and Anne Tj{\o}nneland and Anton Potteg{\aa}rd and Jesper Hallas and S{\o}rensen, {Henrik Toft} and S{\o}ren Friis",
year = "2020",
month = "2",
doi = "10.1007/s10552-019-01252-5",
language = "English",
volume = "31",
pages = "139--151",
journal = "Cancer Causes & Control",
issn = "0957-5243",
publisher = "Springer",
number = "2",

}

Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. / Skriver, Charlotte; Dehlendorff, Christian; Borre, Michael; Brasso, Klaus; Larsen, Signe Benzon; Tjønneland, Anne; Pottegård, Anton; Hallas, Jesper; Sørensen, Henrik Toft; Friis, Søren.

I: Cancer Causes and Control, Bind 31, Nr. 2, 02.2020, s. 139-151.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study

AU - Skriver, Charlotte

AU - Dehlendorff, Christian

AU - Borre, Michael

AU - Brasso, Klaus

AU - Larsen, Signe Benzon

AU - Tjønneland, Anne

AU - Pottegård, Anton

AU - Hallas, Jesper

AU - Sørensen, Henrik Toft

AU - Friis, Søren

PY - 2020/2

Y1 - 2020/2

N2 - Purpose: Epidemiologic studies suggest that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. We examined these associations overall and according to clinical and lifestyle parameters. Methods: We identified male participants in the Danish Diet, Cancer and Health Study (n = 26,339), holding information on anthropometric measures and lifestyle factors. From Danish nationwide registries and medical records, we retrieved complete prescription histories and prostate cancer occurrence and characteristics. Cox regression was used to estimate hazard ratios (HRs) for prostate cancer associated with low-dose aspirin or nonaspirin NSAID use, overall and by clinical characteristics, anthropometric measures, and lifestyle factors. Results: We identified 1,927 prostate cancer cases during a median follow-up of 17.0 years. Low-dose aspirin use was not associated with overall prostate cancer risk, but a reduced HR for nonaggressive prostate cancer (high use [≥ 1,825 tablets]: 0.79; 95% confidence interval (CI) 0.60–1.04) and an increased HR for aggressive disease (high use: 1.27; 95% CI 1.00–1.61) was observed with low-dose aspirin use. Long-term, high-intensity use (≥ 10 years with ≥ 0.25 defined daily doses/day) of nonaspirin NSAIDs was associated with an increased HR for prostate cancer (1.35, 95% CI 0.99–1.84), confined to localized and nonaggressive disease. No consistent variation in HRs was seen in analyses stratified by height, body mass index, smoking, and alcohol use. Conclusion: Low-dose aspirin or other NSAID use was not associated with reduced prostate cancer risk, neither overall nor according to anthropometric measures, smoking, or alcohol use. The variation according to outcome characteristics warrants further investigation.

AB - Purpose: Epidemiologic studies suggest that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. We examined these associations overall and according to clinical and lifestyle parameters. Methods: We identified male participants in the Danish Diet, Cancer and Health Study (n = 26,339), holding information on anthropometric measures and lifestyle factors. From Danish nationwide registries and medical records, we retrieved complete prescription histories and prostate cancer occurrence and characteristics. Cox regression was used to estimate hazard ratios (HRs) for prostate cancer associated with low-dose aspirin or nonaspirin NSAID use, overall and by clinical characteristics, anthropometric measures, and lifestyle factors. Results: We identified 1,927 prostate cancer cases during a median follow-up of 17.0 years. Low-dose aspirin use was not associated with overall prostate cancer risk, but a reduced HR for nonaggressive prostate cancer (high use [≥ 1,825 tablets]: 0.79; 95% confidence interval (CI) 0.60–1.04) and an increased HR for aggressive disease (high use: 1.27; 95% CI 1.00–1.61) was observed with low-dose aspirin use. Long-term, high-intensity use (≥ 10 years with ≥ 0.25 defined daily doses/day) of nonaspirin NSAIDs was associated with an increased HR for prostate cancer (1.35, 95% CI 0.99–1.84), confined to localized and nonaggressive disease. No consistent variation in HRs was seen in analyses stratified by height, body mass index, smoking, and alcohol use. Conclusion: Low-dose aspirin or other NSAID use was not associated with reduced prostate cancer risk, neither overall nor according to anthropometric measures, smoking, or alcohol use. The variation according to outcome characteristics warrants further investigation.

KW - Aspirin

KW - Cohort study

KW - Epidemiology

KW - Nonsteroidal anti-inflammatory drugs

KW - Prostate neoplasms

KW - Risk

U2 - 10.1007/s10552-019-01252-5

DO - 10.1007/s10552-019-01252-5

M3 - Journal article

C2 - 31823168

AN - SCOPUS:85076589469

VL - 31

SP - 139

EP - 151

JO - Cancer Causes & Control

JF - Cancer Causes & Control

SN - 0957-5243

IS - 2

ER -